The utility of the early intervention by the multi-disciplinary cooperation in the skin reaction due to EGFR inhibitor: Phase II study

The utility of the early intervention by the multi-disciplinary cooperation in the skin reaction due to EGFR inhibitor: Phase II study - The utility of the early intervention by the multi-disciplinary cooperation in the skin reaction due to EGFR inhibitor: Phase II study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028286

Enrollment

Registered

2017-09-01

Start date

2017-09-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer, head and neck cancer

Interventions

We conduct an introduction to the chemotherapy center from diagnosis and treatment department, and, in chemotherapy center, a medical oncologist, a pharmacist or a nurse conducts side effect monitorin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who are given EGFR inhibitor with a newcomer The patients who have experience using EGFR inhibitors, but do not have skin symptoms at the time of re-administration

Exclusion criteria

Exclusion criteria: The patients that an agreement was not obtained The patients who have difficulty in side effect monitoring

Design outcomes

Primary

Measure	Time frame
Severe skin reaction incidence	—

Secondary

Measure	Time frame
utility of the episode of care sheet TTF Chemotherapy cancellation ratio due to the skin reaction	—

Countries

Japan

Contacts

Public ContactShohei Sano

Wakayama Medical University hospital Pharmacy

s-sano@wakayama-med.ac.jp073-447-2300

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026